|
Download Annual Meeting Brochure
Meeting Committee
Meeting Program:
 Partnering Meetings
Registration:
Sponsors:
Tech Fair
Sign up for the LES Member Cabaret
Apply for a spot in the LES Band
Miscellaneous Info
|
Plenary Sessions
Monday | Tuesday, October 19
MONDAY, OCTOBER 18
9:00-9:15 a.m.
Welcoming Remarks
9:15-10:30 a.m.
Partnering Deals: Solutions Through Synergy
At the LES 2003 Annual Meeting, we introduced the opening
plenary panel "Leaders of Corporate Licensing." The dialogue
with this group of senior executives, each heading the
licensing function at a major corporation, was an extremely
successful start to the meeting. Based on questions from
attendees during the 2003 session and subsequent feedback
received, the 2004 Annual Meeting opening plenary panel will
focus on high profile licensing deals and the partners involved
in those deals. In this panel we will explore how the deals
came about, the challenges that were faced and the synergies
that were created through the partnership. Questions will be
taken from the audience. The panel will be moderated by the
President of LES (U.S.A. and Canada).
Panel:
Amgen/Biovitrum
Amgen/Biovitrum is one of
the largest international license
and collaboration deals ever done,
providing for the development and
commercialization of small molecule
inhibitors of the 11§HSD1 enzyme for
the treatment of metabolic disorders,
such as type 2 diabetes.
Amgen is a global biotechnology
company that discovers, develops,
manufactures and markets important
human therapeutics based on advances
in cellular and molecular biology.
Biovitrum is a privately-held biotech
company active in the discovery and
development of drugs to treat metabolic
diseases, such as type 2 diabetes and
obesity, and also in the contract process
for development and manufacturing of
protein therapeutics.
Speakers:
Scott Foraker, Vice President, Licensing, Amgen Inc.
Scott Foraker has been
responsible for Amgen's
licensing and acquisition
of new products and technologies since
November 1999. Additionally, he was
in charge of integrating Immunex into
Amgen in 2002. Prior to November 1999,
he served as Associate General Counsel
of Amgen, with responsibility for the
International, Licensing and Corporate
Development functions. Prior to joining
Amgen in 1994, he practiced law at
McDonnell Douglas and Latham &
Watkins.
Paul de Potocki, Senior Vice President,
Commercial Operations,
Biovitrum AB
Paul de Potocki leads
the development of
Biovitrum's sales and
marketing capabilities. During the
two years following the founding of
Biovitrum, he has also directed
Biovitrum's out-licensing and partnering
efforts and was responsible for negotiating
Biovitrum's partnerships with both
GSK and Amgen. Mr. de Potocki has
fifteen years experience from a variety
of international sales, marketing and
business development capacities with
the Pharmacia Group and Unilever.
Massachusetts Institute of Technology/Momenta
Pharmaceuticals, Inc.
The Massachusetts Institute of
Technology (MIT), one of the nation's
most prestigious academic institutions.
MIT has a long tradition of working on
practical problems affecting society and
the economy, and has become a leader
in developing collaborative partnerships
with industry as well as forming
new businesses based upon MIT technology.
One such company is Momenta
Pharmaceuticals, Inc. a biotechnology
company specializing in the detailed
structural analysis and design of complex
sugars for the development of
improved versions of existing drugs,
the development of novel drugs, and
the discovery of new biological
processes. Started in 2001 from
technology developed at MIT,
Momenta raised $17MM in their
first venture round. The Momenta
technology provides a more complete
understanding of the roles that sugars
play in cellular function, disease and
drug action.
Speakers:
Lita Nelsen, Director, Technology
Licensing Office, Massachusetts Institute
of Technology
Lita Nelsen manages over
400 new inventions per year from MIT,
the Whitehead Institute, and Lincoln
Laboratory. Typically, they negotiate over
100 licenses, and start up over 20 new
companies per year. Ms. Nelsen earned
B.S. and M.S. degrees in Chemical
Engineering from MIT and an M.S.
in Management from MIT as a Sloan
Fellow. Prior to joining the MIT
Technology Licensing Office, Ms. Nelsen
spent 20 years in industry.
Susan K. Whoriskey, Ph.D., Vice President,
Licensing and Business Development, Momenta
Pharmacenticals, Inc.
Susan K. Whoriskey,
Ph.D. has been with
Momenta since January 2002. From
September 2001 to January 2002, Dr.
Whoriskey was a biotechnology consultant
to Polaris Venture Partners,
a venture capital firm, where she implemented
the business operations of
Momenta. Formely, Dr. Whoriskey held
various management positions at Cubist
Pharmaceuticals, Inc. Dr. Whoriskey
received her B.S. in Microbiology from
the University of Massachusetts and her
Ph.D. in Molecular Biology from the
University of California, Los Angeles.
STMicroelectronics, Inc./
Hewlett Packard
Hewlett Packard is a technology
solutions provider to consumers, businesses
and institutions globally. The
company's offerings span IT infrastructure,
personal computing and access
devices, global services and imaging
and printing. STMicroelectronics is a
global independent semiconductor
company and a leader in developing
and delivering semiconductor solutions
across the spectrum of microelectronics
applications. An unrivaled combination
of silicon and system expertise, manufacturing
strength, intellectual property
portfolio and strategic partners positions
the company at the forefront of
System-on-Chip (SoC) technology. Its
products play a key role in enabling
today's convergence trends. HP and ST
established a mutually beneficial technology
development relationship that
has produced many fruits, benefiting
both companies and consumers.
Speakers:
Lisa K. Jorgenson,
Vice President,
Intellectual Property
and Licensing,
STMicroelectronics, Inc.
Lisa Jorgenson leads a
multinational IP team in the semiconductor
industry, responsible for all forms
of IP protection and licensing at
STMicroeletronics, a Franco-Italian
company headquartered in Geneva,
Switzerland. Prior to joining ST in 1990,
Ms. Jorgenson was in private practice in
commercial litigation in Dallas at the
firm of Bickel & Brewer.
Joseph Beyers,
Vice President,
Intellectual Property
Licensing, Hewlett
Packard
Joseph Beyers is responsible
for creating and driving
an HP intellectual property strategy
and for driving initiatives to increase
the value realized by HP from its IP
portfolio. Previously Mr. Beyers was
Vice President and General Manager
of Strategic Planning and Business
Development for Hewlett-Packard's
Computer Systems Business. He was
responsible for strategic and tactical
planning for HP's Computer Systems
Business that included HP's PC, workstation,
server, storage and software
businesses.
Procter & Gamble
Company/Corium International, Inc.
A disruptive technology to the traditional transdermal market promises to change the rules of the game. In order to market this revolutionary technology effectively, a new process for seeking a licensee was used that benefited everyone involved. P&G developed an innovative "microneedle" technology that enables topical delivery of skin actives and drugs. In order to bring the technology to market quickly and effectively, P&G employed an auction approach, posting the portfolio on-line and choosing the best candidate based on due diligence criteria. Both companies benefited from the auction process. For Corium, the microdevice would complement their existing core technology and open an entirely new array of drugs for delivery. For P&G, the auction process helped identify a strategic partner that otherwise might not have been approached and that is uniquely qualified to take advantage of the opportunity.
Two billion times a day P&G brands touch the lives of people around the world. The company has one of the largest and strongest portfolios of trusted, quality brands, including Pampers®, Tide®, Bounty®, Pringles®, Folgers®, Charmin®, Iams® and Crest®.
Corium International, Inc. specializes in dermal, transdermal, mucosal and transmucosal drug delivery platforms and manufacturing systems. Corium uses a Total Process Approach to develop and manufacture delivery systems for use in immediate, intermittent and controlled release drug products.
Speaker:
Mark J. Peterson,
Director, External
Business Development
and Global Licensing,
Procter & Gamble
Company
Mark J. Peterson has responsibility for
in-licensing technology that has been
invented elsewhere, as well as out-licensing
technology that has been invented
inside Procter & Gamble. Mr. Peterson
joined Procter & Gamble in 1977 as a
Sales Representative in Commercial
Products. Since that time he has held
various positions within the company,
both in the U.S. and Canada.
12:30-2:00 p.m.
Lunch
Managing a Controversial Brand
Keynote Speaker:
Christie Hefner, Chairman and Chief
Executive Officer, Playboy Enterprises, Inc.
Christie Hefner oversees
policy, management and
strategy in all areas of Playboy Enterprises.
She joined Playboy in 1975 and worked in a
variety of the Company's businesses before
being named president in 1982. In 1988,
she was elected to her present position of
Chairman and CEO with the New York Stock
Exchange-listed international media and
entertainment company. She is also a board
member of the Playboy Foundation, the
Company's philanthropic arm.
In addition to directing Playboy
Enterprises' operations, Ms. Hefner serves
on the board and Audit Committee of
MarketWatch.com, the boards of Canyon
Ranch Health Resort, the Magazine
Publishers Association, the Business
Committee for the Arts, and the board of
governors of the Museum of Television
& Radio Media Center.
TUESDAY, OCTOBER 19
9:00-9:45 a.m.
2004 LES Foundation Lecture
Award Recipient
Transaction Costs and
Antitrust Concerns in the
Licensing of Intellectual
Property
Richard A. Posner,
Judge, United States
Court of Appeals for
the Seventh Circuit
Following his graduation
from Harvard Law
School, Judge Posner
clerked for Justice William J. Brennan Jr.
From 1963-65, he was assistant to
Commissioner Philip Elman of the
Federal Trade Commission. For the next
two years he was assistant to the Solicitor
General of the United States. Prior to
going to Stanford Law School in 1968 as
Associate Professor, Judge Posner served
as General Counsel of the President's Task
Force on Communications Policy. He was
Lee and Brena Freeman Professor of Law
prior to his appointment in 1981 as a
Judge of the U.S. Court of Appeals for the
Seventh Circuit. He was the chief judge of
the court from 1993 to 2000.
9:45-10:30 a.m.
Discovering and Developing
Novel Medicines in the
21st Century: Challenges
and Opportunities for
Licensing
Raymond V. Gilmartin,
President and Chief
Executive Officer, Merck
& Co., Inc.
Raymond V. Gilmartin
joined Merck & Co., Inc.,
in June 1994. Prior to joining Merck,
Mr. Gilmartin was Chairman, President
and Chief Executive Officer of Becton
Dickinson and Company. He joined that
company in 1976 as Vice President,
Corporate Planning, taking on positions
of increasing responsibility over the next
18 years. Mr. Gilmartin serves on the
boards of directors of General Mills, Inc.
and the Microsoft Corporation.
10:30-11:00 a.m. Coffee Break
11:00 a.m.-11:45 a.m.
Mediation of High Stakes
Intellectual Property Cases:
New Models to Meet New
Challenges
Eric D. Green, Professor, Boston
University School
of Law
Professor Eric D. Green
teaches negotiation,
mediation, complex ADR
processes, resolution of mass torts and
evidence at Boston University School of
Law. He is a co-founder and principal of
RESOLUTIONS, LLC, a mediation, arbitration
and ADR provider in Boston, MA.
He was a co-founder of JAMS/ENDISPUTE
and a member of the Center for
Public Resources Institute of Dispute
Resolution since its inception. He was a
co-author of the first edition of Dispute
Resolution (with Goldberg and Sander),
and has written many books and articles
on dispute resolution and evidence.
Professor Green maintains an active ADR
practice for complex legally intensive
disputes. Professor Green has successfully
mediated many high stakes cases, including
the United States v. Microsoft
anti-trust case; the MasterCard/Visa
merchants' class action anti-trust case;
the Monsanto PCB cases in Alabama; the
childhood and adult cancer cases in Toms
River, New Jersey; and numerous large
construction cases, including most of the
disputes arising out of the design and
construction of major league baseball and
football stadiums. He has also mediated
many complex, multi-party class action
cases involving mergers and acquisitions,
contract disputes, patent disputes, securities
fraud, accounting problems, mass
torts, employment and consumer claims.
11:45 a.m.-12:30 p.m.
As the Future Catches You
Juan Enriquez,
Chairman and Chief
Executive Officer,
Biotechonomy
The digital revolution
was just the beginning.
According to Juan
Enriquez, author of As the Future
Catches You, the genomics revolution
will be far more powerful. In his presentation,
Mr. Enriquez will reveal why
gene research is the single most important
driver of new computers and software
in places like IBM, Compaq, and
Sun Microsystems, why cosmetics companies
are hiring molecular biologists,
why energy companies are thinking
about very different ways to generate
renewable fuels, and how seed companies
have become information-processing
companies. You will discover how
biocomputing could make genomes
the world's most powerful and compact
coding and information systems, blending
the genomic revolution with the
computer revolution.
Juan Enriquez is a best-selling author,
businessman, and academician. He
is currently Chairman and CEO of
Biotechonomy, a company that is
researching and funding start-ups to
enable the genomic revolution. Founding
director of the Harvard Business School
Life Science Project and author of global
bestseller As the Future Catches You:
How Genomics & Other Forces are
Changing Your Life, Work, Health
& Wealth. (Random House/ Crown,
September 2001), he is recognized as one
of the world's leading authorities on the
economic and political impacts of life
sciences. Mr. Enriquez serves on a variety
of boards including Cabot Microelectronics,
The Center for the Advancement of
Genomics, The Harvard Medical School
Genetics Advisory Council, The USDA
Advisory Committee on Biotechnology
Group, The Chairman's International
Council of the America's Society, and the
Visiting Committee of Harvard's David
Rockefeller Center.
|
